Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E3 | Q9Y5X4 | 7/20 | 0.41 |
| ▸ | ACP1 | P24666 | 1/20 | 0.39 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | FABP6 | P51161 | 1/20 | 0.37 |
| ▸ | CLK2 | P49760 | 1/20 | 0.36 |
| ▸ | PRKX | P51817 | 1/20 | 0.36 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.36 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | F7 | P08709 | 1/20 | 0.35 |
| ▸ | F3 | P13726 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335393 | 0.89 | ACP1 (0.42) | NR2E3ACP1SIRT4ABL1FABP6 | |
| SCHEMBL335249 | 0.81 | ACP1 (0.39) | NR2E3ACP1SIRT4ABL1FABP6 | |
| SCHEMBL15282254 | 0.78 | DGAT1 (0.41) | NR2E3ACP1SIRT4ABL1FABP6 | |
| SCHEMBL4123591 | 0.77 | ACP1 (0.48) | NR2E3ACP1SIRT4ABL1FABP6 | |
| SCHEMBL4109421 | 0.77 | ACP1 (0.48) | NR2E3ACP1SIRT4ABL1FABP6 | |
| SCHEMBL335832 | 0.77 | ACP1 (0.48) | NR2E3ACP1SIRT4ABL1FABP6 | |
| SCHEMBL4100714 | 0.76 | ABL1 (0.52) | NR2E3ACP1SIRT4ABL1FABP6 | |
| SCHEMBL15282285 | 0.74 | ACP1 (0.46) | NR2E3ACP1SIRT4ABL1FABP6 | |
| SCHEMBL15282212 | 0.74 | ACP1 (0.46) | NR2E3ACP1SIRT4ABL1FABP6 | |
| SCHEMBL4108132 | 0.73 | HTR3E (0.54) | NR2E3SIRT4ABL1FABP6DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069289-B1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS | SANOFI SA (FR) | 2013-10-02 | — | — | EP | claimed |
| US-8097758-B2 | Isoserine derivatives for use as coagulation factor IXa inhibitors | SANOFI-AVENTIS (FR) | 2012-01-17 | — | — | US | claimed |
| US-20090233949-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233949-A1 | ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS | TFPI, F2, F9 | NR2E3 4880/4885ACP1 1423/4885SIRT4 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.